Cintirorgon is under clinical development by Lycera and currently in Phase II for Metastatic Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Metastatic Renal Cell Carcinoma have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cintirorgon’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cintirorgon overview

Cintirorgon (LYC-55716) is under development for the treatment of metastatic solid tumors including non-small cell lung cancer (NSCLC), sarcomatoid breast cancer, squamous cell cancer of the head and neck (SCCHN), ovarian cancer, urothelial cancer, gastric and esophageal cancer, bladder cancer, adenocarcinoma of the gastro-esophageal junction and renal cancer. The drug candidate is administered through oral route. The drug candidate acts by targeting retinoid related orphan receptor gamma.

Lycera overview

Lycera is a biopharmaceutical company that focuses on the development of oral immune modulators for the treatment of patients with autoimmune diseases and cancer. The company’s pipeline products include LYC-55716, an oral retinoic acid-related orphan receptor gamma (RORgamma) agonist which is in Phase 1/2a ARGON trial that modulates gene expression to reprogram immune cells for improved function and decrease immunosuppressive mechanisms. It also develops novel ATPase modulators for the treatment of autoimmune diseases; and immuno-oncology targets. Lycera is headquartered in Ann Arbor, Michigan, the US.

For a complete picture of Cintirorgon’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.